Drugs / Investigational RSV vaccine 3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06573281 | Sep 2024 → Apr 2026 overdue | respiratory syncytial virus infectious disease | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Investigational RSV vaccine 3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06573281 ↗ |
| Route | Intramuscular | “Investigational RSV vaccine 3 administered intramuscularly on Day 1 and Day 30.” NCT06573281 ↗ |